Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-25
2005-01-25
Killos, Paul J. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06846823
ABSTRACT:
The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.
REFERENCES:
patent: 4695568 (1987-09-01), Ninomiya et al.
patent: 4939136 (1990-07-01), Haeck et al.
patent: 5225407 (1993-07-01), Oakley et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5663343 (1997-09-01), van der Meij et al.
patent: 5945415 (1999-08-01), Kato et al.
patent: 5962494 (1999-10-01), Young
patent: 5977127 (1999-11-01), Bonnacker et al.
patent: 6300336 (2001-10-01), Eeckhout et al.
patent: 6355647 (2002-03-01), Steiner et al.
patent: 6440453 (2002-08-01), Fischer et al.
patent: 6465458 (2002-10-01), Wong et al.
patent: 20010020025 (2001-09-01), Megens
patent: 20020002197 (2002-01-01), Mueller et al.
patent: 20020010216 (2002-01-01), Rogosky et al.
patent: 20020107249 (2002-08-01), Wong et al.
patent: 20030158221 (2003-08-01), Zhang et al.
patent: 20030203055 (2003-10-01), Rao et al.
patent: WO 9850037 (1998-11-01), None
patent: WO 0048581 (2000-08-01), None
patent: WO 0126623 (2001-04-01), None
patent: WO 02094249 (2002-11-01), None
patent: WO 03061657 (2003-07-01), None
patent: WO 03063873 (2003-08-01), None
patent: WO 03077897 (2003-09-01), None
patent: WO 2004004734 (2004-01-01), None
patent: WO 2004019948 (2004-03-01), None
Andersson, K.E., “Treatment of the Overactive Bladder: Possible Central Nervous System Drug Targets,”Urology,59 (Suppl 5A):18-24 (2002).
Andersson, K.E., “Bladder Activation: Afferent Mechanisms,”Urology,59 (Suppl 5A):43-50 (2002).
Morrison, J. et al., “Neurophysiology and Neuropharmacology” In: Incontinence (vol. 2) Abrams, P., Cardozo, L., Khoury, S., and Wein, A., Eds. (UK, Health Publications, Ltd.,) pp. 83-163 (2002).
Owens, M. J. et al., “Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites1,”J. Pharmacol. Exp. Ther.,283(3): 1305-1322 (1997).
Sharma, A. et al., “Pharmacokinetics and Safety of Duloxetine, a Dual-Serotonin and Norepinephrine Reuptake Inhibitor,”J. Clin. Pharmacol.,40:161-167 (2000).
Thor, K. B. et al. “Effects of Duloxetine, a Combined Serotonin and Norephinephrine Reuptake Inhibitor, on Central Neural Control of Lower Urinary Tract Function in the Chloralose-Anesthetized Female Cat,”J. Pharmacol. Exp. Ther.,274: 1014-1024 (1995).
Downie, J.W., “Pharmacological Manipulation of Central Micturition Circuitry,”Curr. Opin. CPNS Inves. Drugs,1(2):231-239 (1999).
Khan, M.A. et al., “Doxazosin Modifies Serotonin-Mediated Rabbit Urinary Bladder Contraction. Potential Clinical Revelance,”Urol Res.,28:116-121 (2000).
Metts, J. F., “Interstitial Cystitis: Urgency and Frequency Syndrome,”American Family Physician,64(7):1199-1206 (2001).
Theoharides, T. C. and Sant, G.R., “New Agents for the Medical Treatment of Interstitial Cystitis,”Exp. Opin. Invest. Drugs,10(3): 521-546 (2001).
Collins M.M. et al., “How Common is Prostatitis? A National Survey of Physician Visits,”J. Urol.,159:1224-1228 (1998).
Eguchi, J. et al., “Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride,”Arzneim.-Forschung/Drug Res.,47(12): 1337-47 (1997).
Wood, J.D. et al. “Fundamentals of Neurogastroenterology,”Gut,45(Suppl II):II6-II16 (1999).
Center for Drug Evaluation and Research Application No.: 020623: Pharmacology Reviews; Jul. 5, 1996.
Kilpatrick, G.J. et al., “Identification and Distribution of 5-HT3Receptors in Rat Brain Using Radioligand Binding,”Nature,330: 746-748 (1987).
Butler, A. et al., “Pharmacological Properties of GR38032F, a Novel Antagonist at 5-HT3Receptors,”Br. J. Pharmacol.,94(2): 397-412 (1988).
Ito, C. et al., “Effect of GK-128 [2-[(2-Methylimidazol-1-yl)methyl]-benzo[f]thiochromen-1-one Monohydrocholoride Hemihydrate], a Selective 5-Hydroxytryptamine3Receptor Antagonist, on Colonic Function in Rats,”J. Pharmacol. Exp. Ther.,280(1): 67-72 (1997).
Chuang, Y.C. et al., “Intravesical Protamine Sulfate and Potassium Chloride as a Model for Bladder Hyperactivity,”Urology,61(3): 664-670 (2003).
Sasaki, K. et al., “Diabetic Cystopathy Correlates with a Long-Term Decrease in Nerve Growth Factor Levels in the Bladder and Lumbosacral Dorsal Root Ganglia,”J. Urol.,168(3): 1259-1264 (2002).
Yoshimura, N. and Chancellor, M. B., “Current and Future Pharmacological Treatment for Overactive Bladder,”J. Urol.,168:1897-1913 (2002).
Appell, R. A. et al., “Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study,”Mayo Clin. Proc.76:358-363 (2001).
Elmiron® (pentosan polysulfate sodium), capsules,Product Information,Ortho-McNeil Pharmaceutical,Inc., Ranitan, N.J. (2002).
Elliot, D. S. et al., “Medical Management of Overactive Bladder,”Mayo Clin. Proc.76:353-355 (2001).
Tonini, M. et al., “Characterization of the 5-HT Receptor Potentiating Neuromuscular Cholinergic Transmission in Strips of Human Isolated Detrusor Muscle,”Br. J. Pharmacol.,113(1):1-2 (1994).
Espey, M.J. et al., “Serotonergic Modulation of Spinal Ascending Activity and Sacral Reflex Activity Evoked by Pelvic Nerve Stimulation in Cats,”Brain Res.,798(1-2):101-108 (1998).
Yoshida, A. et al., “5-Hydroxytryptamine Receptors, Especially the 5-HT4Receptor, in Guinea Pig Urinary Bladder,”Jpn. J. Pharmacol.,89(4):349-355 (2002).
Kodama, M. and Takimoto, Y., “Influence of 5-Hydroxytryptamine and the Effect of a New Serotonin Receptor Antagonist (Sarpogrelate) on Detrusor Smooth Muscle of Streptozotocin-Induced Diabetes Mellitus in the Rat,”International Journal of Urology 7:231-235 (2000).
Katofiasc, M. A. et al., “Comparison of the Effects of Serotonin Selective, Norepinephrine Selective, and Dual Serotonin and Norepinephrine Reuptake Inhibitors on Lower Urinary Tract Function in Cats,”Life Sci.,71:1227-1236 (2002).
Andersson, K. E., “Treatment of Overactive Bladder: Other Drug Mechanisms,”Urology,55(Supplement 5A):51-59 (2000).
Testa, R. et al., “Effect of Different 5-Hydroxytryptamine Receptor Subtype Antagonists on the Micturition Reflex in Rats,”BJU Int.,87(3):256-264 (2001).
Barras, M. et al., “Characterisation of the 5-HT Receptor Potentiating Neurotransmission in Rabbit Bladder,”Eur. J. Pharmacol.,318(2-3):425-428 (1996).
Eguchi, J. et al., “The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor with 5-HT3Receptor Antagonism,”Pharm., Biochem. and Behavior 68:677-683 (2001).
Burns, M. J.; The Pharmacology and Toxicology of Reboxetine, [Retrieved from the Internet Dec. 4, 2002]. Retrieved from the Internet <http://www.ijmt.net/3_4/3_4_26.html>.
Bymaster, F. P. et al., “Comparative Affinity of Duloxetine and Venlafaxtine for Serotonin and Norepinephrine
Fraser Matthew O.
Landau Steven B.
Miller Cheryl L.
Dynogen Pharmaceuticals, Inc.
Hamilton Brook Smith & Reynolds P.C.
Killos Paul J.
LandOfFree
Method of treating lower urinary tract disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating lower urinary tract disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating lower urinary tract disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401464